Stay updated on Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.

Latest updates to the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page
- Check4 days agoChange DetectedNo additions or deletions were detected on the Study Details page for NCT03586024 between the old and new screenshots. Core elements such as eligibility criteria, study design, and key sections remain unchanged.SummaryDifference0.5% 
- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedAdded a government-operating-status notice and new version v3.2.0; removed old version v3.1.0.SummaryDifference4% 
- Check32 days agoChange DetectedUpdate: revision tag changed from v3.0.2 to v3.1.0; no substantive content changes detected.SummaryDifference0.1% 
- Check47 days agoChange DetectedVersion updated to v3.0.2; older v3.0.1 tag and the Back to Top element were removed.SummaryDifference0.3% 
- Check54 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content.SummaryDifference0.3% 
- Check61 days agoChange DetectedThe web page has undergone significant changes, including the addition of a facility name and location, as well as the introduction of new content related to Hemic and Lymphatic Diseases and pembrolizumab. However, many specific disease-related terms and previous location details have been removed.SummaryDifference4% 
Stay in the know with updates to Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in NK/T & EBV+ DLBCL: Clinical Trial page.